Optimal role of temozolomide in the treatment of malignant gliomas
Author:
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,General Neuroscience
Link
http://link.springer.com/content/pdf/10.1007/s11910-005-0047-7.pdf
Reference66 articles.
1. Stupp R, Gander M, Leyvraz S, et al.: Current and future developments in the use of temozolomide in the treatment of brain tumors. Lancet Oncol 2001, 2:552–560.
2. Yung WK, Prados MD, Yaya-Tur R, et al.: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999, 17:2762–2771.
3. Yung WK, Albright RE, Olson J, et al.: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83:588–593.
4. Brada M, Hoang-Xuang K, Rampling R, et al.: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001, 12:259–266.
5. Chang SM, Theodosopoulos P, Lamborn K, et al.: Temozolomide in the treatment of recurrent malignant glioma. Cancer 2004, 100:605–611.
Cited by 172 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Validating a clinically based MS-MLPA threshold through comparison with Sanger sequencing in glioblastoma patients;2024-09-08
2. Two decades of progress in glioma methylation research: the rise of temozolomide resistance and immunotherapy insights;Frontiers in Neuroscience;2024-09-02
3. Glioblastoma Neurovascular Progenitor Orchestrates Tumor Cell Type Diversity;2024-07-24
4. Selective regulation of chemosensitivity in glioblastoma by phosphatidylinositol 3-kinase beta;iScience;2024-06
5. Do presenting symptoms predict treatment decisions and survival in glioblastoma? Real-world data from 1458 patients in the Swedish brain tumor registry;Neuro-Oncology Practice;2024-04-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3